Navigation Links
Multi Merci Trial Results Published in Peer Reviewed Journal
Date:3/6/2008

MOUNTAIN VIEW, Calif., March 6 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the results of its Multi MERCI trial will be published in the April 2008 edition of the medical journal, Stroke. The Multi MERCI trial was the second trial studying safety and efficacy of the Merci Retrieval System(TM), a "corkscrew-type" device that is delivered into the brain and is designed to restore blood flow by engaging, capturing and removing blood clots that cause ischemic stroke. The full, peer reviewed trial results are available now to online subscribers. Stroke is published by the American Heart Association.

In the Multi MERCI trial, patients treated with the newer Merci(R) L5 Retriever had their cerebral blood flow successfully restored 57.3% of the time with the Merci Retrieval System alone. With the addition of adjunctive therapy, physicians successfully restored cerebral blood flow 69.5% of the time. For patients to be successfully revascularized, not only the target vessel, but all treatable downstream vessels needed to achieve TIMI 2 or 3 flow.

In addition, a total of 36% of all patients treated achieved a "good" outcome at 90 days post procedure, a higher rate than reported in any other device trial in large vessel acute ischemic stroke patients. Ninety-day clinical outcomes in stroke trials are generally measured using the modified Rankin Score, a measure of functional independence, with a score of 2 or less considered a good outcome. These outcome data are superior to those reported in recent studies of other devices in which successful revascularization was not as stringently defined.

Multi MERCI was a multi-center, prospective trial including 164 patients treated at 15 hospitals in the United States and Canada. All patients had moderate-to-severe, large vessel ischemic strokes. The trial included patients who were ineligible for or had failed treatm
'/>"/>

SOURCE Concentric Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
2. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
3. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
4. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
5. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... WASHINGTON, Nov. 1 Multiple myeloma is one,of the ... U.S., but,survival rates have risen dramatically over the past ... to new types of drugs,and aggressive therapeutic interventions such ... studies prepublished online in Blood, the,official journal of the ...
... IRVINE, Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: ... data,from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). ... funded cooperative,group study conducted by the Children,s Oncology Group ... of patients originally treated in the Phase,3 trial. The ...
Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
(Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
(Date:7/31/2014)... USHIO America’s Solid State Lighting ... lighting marketplaces, today announced the launch of its ... users to transform existing, inefficient lamp-based downlights to ... USHIO America’s Uphoria LED downlight retrofit kits fit ... the user to upgrade old incandescent recessed lighting ...
(Date:7/31/2014)... 2014 When guests shop CVS, they’ll find ... to Shea Moisture. And now CVS is adding another acclaimed ... August 1, guests will find G Natural products in CVS ... investment, CEO Roger Gore was inspired to start G’Natural Herbal ... and developing a receding hairline; he tried many products on ...
(Date:7/30/2014)... Calling all runners in the Richmond, VA region. , Tidewater ... monthly Runner’s Injury Clinic at the Glen Allen ... Monday of each month through the end of the year ... December 8. , The clinics run from 5:30 to ... and attire, will receive a complimentary evaluation of running injuries ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 WalkingSticksandCane.com ... Walking Canes. The ladies will love the new European fashions ... Sticks . These sticks and canes are from one from ... England. Each of the styles re unique and offer the ... , The Blackthorn Walking Sticks are some of the rarest ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 3Health News:European Walking Sticks from WalkingSticksandCane.com 2
... may be sharply divided in their views on many aspects ... in strong agreement when it comes to one of the ... According to results of the American College of Surgeons (ACS) ... support the establishment of a nationwide trauma system - including ...
... Most pregnant women consuming a typical,western diet obtain too ... which is critical for fetal and infant brain,development. This ... panel of nutrition experts summarized in the September 2007,Fats ... called,for pregnant and lactating women to consume at least ...
... a Top ... Priority at Newton-Wellesley, RESTON, Va. and ... announced Newton-Wellesley,s use of,the Isabel decision support system to aid ... the implementation,kicks off an initiative to affirm the quality of ...
... MESA, Ariz., Oct. 3 The Well Life Center ... and healthcare,education, announces the launch of its "10 Healing ... Donations benefit The Arizona,Special Olympics. This session will ... using the 10 universal laws. Discover how to set ...
... Prism Pharmaceuticals,Inc., a privately-held, specialty pharmaceutical company committed ... the appointment of Maurits W. Geerlings, MD, MBA, ... "I am pleased to welcome Dr. Geerlings to ... brings a tremendous amount of relevant,industry experience and ...
... Recently, a man, traveling on,business to Scranton, ... by,ambulance to Moses Taylor Hospital where clinicians identified ... recent seizure, the patient was unable to,communicate his ... registration, a form automatically printed out in the ...
Cached Medicine News:Health News:A nation divided over health care? Not so fast 2Health News:Brain, Eye and Heart Health: Three Reasons to Eat More Omega-3s 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 3Health News:Moses Taylor Hospital Automates Medication Reconciliation 2
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: